Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTR | Q99707 | 1/20 | 0.38 |
| ▸ | SCN1A | P35498 | 10/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 10/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8479247 | 0.86 | SCN1A (0.37) | MTRSCN1ASCN5ASCN9AAOC3 | |
| SCHEMBL8487928 | 0.84 | SCN1A (0.36) | MTRSCN1ASCN5ASCN9AAOC3 | |
| SCHEMBL8485124 | 0.84 | OPRK1 (0.33) | — | |
| SCHEMBL8479611 | 0.83 | SCN1A (0.35) | MTRSCN1ASCN5ASCN9AAOC3 | |
| SCHEMBL8485150 | 0.82 | L3MBTL1 (0.41) | GAANPSR1 | |
| SCHEMBL8664326 | 0.81 | MTR (0.35) | MTRSCN1ASCN5ASCN9AAOC3 | |
| SCHEMBL8668077 | 0.81 | OPRK1 (0.32) | — | |
| SCHEMBL8664250 | 0.80 | SCN1A (0.34) | MTRSCN1ASCN5ASCN9AAOC3 | |
| SCHEMBL8595907 | 0.80 | MTR (0.46) | MTRSCN1ASCN5ASCN9AAOC3 | |
| SCHEMBL8485591 | 0.79 | NPY1R (0.41) | MTRSCN1ASCN5ASCN9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5883099-A | TREATMENT OF ATHERSCLEROSIS, PANCREATITIS OBESITY OR HYPERGLYCEMIA | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-16 | — | — | US | disclosed |
| US-5739135-A | PREVENTING OR TREATING ATHEROSCLEROSIS, PANCREATITIS SECONDARY TO HYPERTRIGLYCERIDEMIA, HYPERGLYCEMIA, OBESITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-14 | — | — | US | disclosed |